News

This addition of a new reimbursement category will allow more people the opportunity for better diabetes management

Researchers used Terumo Health Outcomes’ ePRISM® software to calculate safe contrast volume targets and improve overall patient outcomes

Next-generation platform makes hollow-fiber perfusion technology commercially relevant and delivers advanced software to support cGMP

Radial approach allowed for 92.3% same day discharge with no serious adverse events in prospective post-market study

First Neutralized Peritoneal Dialysis Solution for Patients in China

Terumo Blood and Cell Technologies’ new Rika system represents a new era in plasma collections

Expected to Reduce the Burden on Patients Receiving Chemotherapy

Combination of apheresis and Galectin-3 (Gal-3) expertise is expected to result in potential therapeutic option for unmet medical needs

Unique collaboration begins to link the CGT supply chain from end to end to tackle hard scale-up and quality challenges across the industry

Adoption of Terumo Blood and Cell Technologies’ Spectra Optia will Save the UK’s NHS an Expected GBP 13 Million per Year

Late Breaking Trial Presentation at EuroPCR 2022 with Simultaneous Publication in the Journal of the American College of Cardiology (JACC)

Contributing to Terumo Group’s Core Technology in Diabetes Care, ME Devices and Neurovascular Treatment

Adjunctive use of Blood Glucose Meter Principally Not Required